21Jun/13

Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment – Proactive Investors USA & Canada


Proactive Investors USA & Canada

Fusion IP’s Diurnal gets European boost for infant hydrocortisone treatment
Proactive Investors USA & Canada
Diurnal, one of Fusion IP’s (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric 
Beaufort Securities Breakfast Today including Fusion IPProactive Investors UK

all 3 news articles »

21Jun/13

Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment – Proactive Investors Australia

Fusion IP’s Diurnal gets European boost for infant hydrocortisone treatment
Proactive Investors Australia
Diurnal, one of Fusion IP’s (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric 

and more »